SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple Turns 50: From Garage Startup to AI Crossroads 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
NEW YORK, Jan. 06, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Inotek Pharmaceuticals Corporation (“Inotek”) (NASDAQ:ITEK) between July 23, 2015 and December 30, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra/inotek-pharmaceuticals-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Inotek misrepresented the efficacy of its drug candidate trabodenoson—the only drug Inotek currently has in its clinical development pipeline—and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. In particular, it is alleged that the Company made positive statements about the drug despite knowledge that the MATrX-1 phase 3 clinical trial of trabodenoson would fail to meet its primary endpoint of statistical relevance in the reduction of intraocular pressure compared with placebo.
On January 3, 2017, Inotek announced that the Phase 3 trial of trabodenoson had failed to achieve this primary endpoint. Following this news, shares of Inotek fell from a closing price of $6.10 on December 30, 2016, to a closing price of of $1.75 per share on January 3, 2017.
If you suffered a loss in Inotek you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
